profit from every $100 of sales.
$0$100
Telix Pharmaceuticals
$9.23-1.39% today
+0.5% in 1 year
1-year low $6.411-year high $12.83
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Telix Pharmaceuticals sold, what it kept, and what it did with the cash.
Sales went from $109 million in 2022 to $804 million in 2025, with -$7.13 million of profit last year.
SalesProfit
Telix Pharmaceuticals vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Telix Pharmaceuticals | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Telix Pharmaceuticals's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 109 | 333 | 517 | 804 | |
| 65 | 210 | 336 | 426 | |
| -50 | 35 | 56 | 18 | |
| -63 | 12 | 62 | 35 | |
| -104 | 4 | 34 | -7 | |
| -0.34 | 0.01 | 0.10 | -0.02 | |
| 59.3% | 62.9% | 65.1% | 53.1% | |
| -46.3% | 10.5% | 10.8% | 2.2% | |
| -95.6% | 1.3% | 6.5% | -0.9% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 174 | 277 | 940 | 1,164 |
| Cash | 116 | 84 | 440 | 142 |
| Total debt | 10 | 12 | 360 | 467 |
| Total liabilities | 175 | 175 | 587 | 749 |
| 54 | 103 | 353 | 415 | |
| 311 | 319 | 345 | 324 | |
| -76.2% | 7.9% | 6.9% | 3.1% | |
| -191.2% | 4.1% | 9.5% | -1.7% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| – | – | – | – | |
| 9 | 7 | 22 | 44 | |
| -78 | 7 | 5 | -61 | |
| Dividends paid | – | – | – | – |
| 8 | – | – | – | |
| – | – | – | – |
Valuation
- –
- 146.0×
- –
- 7.6×
- 3.9×
- –
- 98.2×
- -2.0%
- -0.2%
- 0.0%
Profitability
- 53.1%
- 2.2%
- -0.9%
- 3.0%
- 3.2%
- -16.0%
- -2.1%
- -0.6%
- 1.8%
- 21.3%
Growth
- +94.7%
- –
- −388.4%
- –
- +1.4%
Financial health
- 15.4×
- 1.12
- 44.3%
- 0.9×
- 1.43
- 1.27
- 0.69
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 37%of 964
Bottom 26%of 898
Top 5%of 911
Bottom 25%of 991
What analysts expect
- Average price target
- $17.00
- Range
- $17.00 – $17.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Feb 19, 2026 | -0.01 | 0.03 | −135.4% |
| Aug 20, 2025 | -0.01 | 0.13 | −105.1% |
| Feb 20, 2025 | 0.07 | 0.09 | −25.2% |
| Aug 22, 2024 | 0.02 | 0.09 | −75.0% |
| Dec 31, 2023 | 0.04 | – | – |
| Jun 30, 2023 | -0.03 | 0.04 | −179.9% |
| Dec 31, 2022 | -0.07 | -0.05 | −45.6% |
| Jun 30, 2022 | -0.16 | -0.08 | −92.7% |
News
Telix Pharmaceuticals reports Q3 resultsSeeking Alpha · Oct 21, 2026FDA approves Telix brain cancer imaging drug PixclaraSeeking Alpha · Sep 14, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
21No pass
Benjamin Graham
20No pass
Philip Fisher
42No pass
Peter Lynch
65Pass
Joel Greenblatt
0No pass
Charlie Munger
19No pass
Terry Smith
28No pass
Questions about Telix Pharmaceuticals
Is Telix Pharmaceuticals a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Telix Pharmaceuticals AI analysis
What does Telix Pharmaceuticals do?
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. It is in Biotechnology, based in North Melbourne, VIC, Australia, with 1,120 employees.
Does Telix Pharmaceuticals pay a dividend?
No. Telix Pharmaceuticals does not pay a dividend at the moment.
Is Telix Pharmaceuticals stock halal?
Yes. Telix Pharmaceuticals passes our halal screen: its business is permitted and its debt is 15% of its market value, under the 30% limit. How we check
How has Telix Pharmaceuticals stock done over the past year?
Up 0.5% over the past twelve months, to $9.23. It traded between $6.41 and $12.83 and is 28.1% below its high.
Who are Telix Pharmaceuticals's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Telix Pharmaceuticals's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.